A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Roche
- 14 Dec 2017 Planned number of patients changed from 33 to 48.
- 14 Dec 2017 Planned End Date changed from 15 Aug 2019 to 14 Feb 2020.
- 28 Sep 2017 Planned End Date changed from 14 Sep 2018 to 15 Aug 2019.